MEDI-493 FOR PROPHYLAXIS OF SEVERE RSV DISEASE IN INFANTS

MEDI-493 用于预防婴儿严重 RSV 疾病

• 批准号: 6279174
• 负责人: MARK H SAWYER
• 金额: $ 1.43万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279174
• 关键词: antiviral agents; bronchopulmonary dysplasia; clinical research; clinical trials; drug administration rate /duration; human subject; human therapy evaluation; infant human (0-1 year); otitis media; outcomes research; placebos; premature infant human; respiratory disorder chemotherapy; respiratory disorder epidemiology; respiratory infections; respiratory syncytial virus

Compare the safety and efficacy of MEDI-493 to placebo for the reduction of the incidence of respiratory syncytial virus (rsv) hospitalization among infants born prematurely and infants with bronchopulmonary dysplasia. Determine the effect of monthly prophylaxis compared to placebo on hospitalization outcomes, disease severity, hospitalization for non-rsv respiratory disease and incidence of otitis media.

比较MEDI-493与安慰剂在降低 呼吸道合胞病毒（RSV）住院的发病率 早产儿和支气管肺炎婴儿中 发育不良确定每月一次预防性治疗与安慰剂相比的效果 关于住院结局、疾病严重程度、非RSV住院 呼吸道疾病和中耳炎的发病率。